Ser263
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser263  -  NFAT2 (mouse)

Site Information
ARGsRPTsPCNKRKY   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15412721

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 ) , mass spectrometry (in vitro) ( 1 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
bone cancer ( 1 ) , brain cancer ( 4 , 5 ) , neuroendocrine cancer ( 4 , 5 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 2 ) , 293 (epithelial) ( 1 ) , BMMC (mast) ( 1 ) , brain ( 4 , 5 ) , macrophage-peritoneum [MPRIP (mouse), homozygous knockout] ( 3 ) , U2OS (bone cell) ( 1 )

Upstream Regulation
Regulatory protein:
CCNA2 (human) ( 1 ) , CCNB1 (human) ( 1 )
Putative in vivo kinases:
CDK1 (human) ( 1 )
Kinases, in vitro:
CDK1 (human) ( 1 )
Treatments:
BMI-1026 ( 1 ) , cantharidin ( 1 ) , cytochalasin_D ( 1 ) , etoposide ( 1 ) , FK506 ( 1 ) , insulin ( 2 ) , MK-2206 ( 2 ) , nocodazole ( 1 ) , salubrinal ( 1 ) , seliciclib ( 1 ) , taxol ( 1 )

Downstream Regulation
Effects of modification on NFAT2:
activity, inhibited ( 1 ) , intracellular localization ( 1 )
Effects of modification on biological processes:
cell differentiation, inhibited ( 1 )

References 

1

Kim HM, et al. (2019) Inhibition of osteoclasts differentiation by CDC2-induced NFATc1 phosphorylation. Bone 131, 115153
31730830   Curated Info

2

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

3

Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51
22942356   Curated Info

4

Guo A (2011) CST Curation Set: 12737; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info

5

Guo A (2011) CST Curation Set: 12739; Year: 2011; Biosample/Treatment: tissue, brain/untreated; Disease: brain cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: PXpSP, pSPX(K/R) Antibodies Used to Purify Peptides prior to LCMS: Phospho-MAPK/CDK Substrates (PXSP or SPXR/K) (34B2) Rabbit mAb Cat#: 2325, PTMScan(R) Phospho-MAPK/CDK Substrate Motif (PXS*P, S*PXK/R) Immunoaffinity Beads Cat#: 1982
Curated Info